Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection

Hepatitis B virus （HBV） infection is a global public health problem. Of the approximately 2 billion people who have been infected worldwide, more than 400 million are chronic carriers of HBV. Considerable numbers of chronic HBV carriers suffer from progressive liver diseases. In addition, all HBV carriers are permanent source of this virus. There is no curative therapy for chronic HBV carriers. Antiviral drugs are recommended for about 10% patients, however, these drugs are costly, have limited efficacy, and possess considerable side effects. Recent studies have shown that immune responses of the host to the HBV are critically involved at every stage of chronic HBV infection： （1） These influence acquisition of chronic HBV carrier state, （2） They are important in the context of liver damages, （3） Recovery from chronic HBV-related liver diseases is dependent on nature and extent of HBV-specific immune responses. However, induction of adequate levels of HBV-specific immune responses in chronic HBV carriers is difficult. During the last one decade, hepatitis B vaccine has been administered to chronic HBV carriers as a therapeutic approach （vaccine therapy）. The present regimen of vaccine therapy is safe and cheap, but not so effective. A dendritic cell-based therapeutic vaccine has recently been developed for treating chronic HBV infection. In this review, we will discuss about the concept, scientific logics, strategies and techniques of development of HBV- specific immune therapies including vaccine therapy and dendritic cell-based vaccine therapy for treating chronic HBV infection.

肝炎 B (HBV ) 感染是一个全球公共卫生问题。全球被感染了的约 20 亿个人，超过 4 亿是 HBV 的慢性带菌者。长期的 HBV 搬运人的可观的数字患进步的肝疾病。另外，所有 HBV 搬运人是这个病毒的永久来源。为长期的 HBV 搬运人没有药品治疗。然而，抗病毒的药为大约 10% 病人被推荐这些药是昂贵的，限制了功效，并且拥有可观的副作用。最近的研究证明了到 HBV 的主人的有免疫力的回答非常在长期的 HBV 感染的每个阶段被包含：(1 ) 这些影响长期的 HBV 带菌状态的获得，(2 ) 他们在肝损坏的上下文是重要的，(3 ) 从长期的 HBV 相关的肝疾病的恢复依赖于 HBV 特定的有免疫力的回答的自然和程度。然而，在长期的 HBV 搬运人的 HBV 特定的有免疫力的回答的足够的层次的正式就职是困难的。在最后一十年期间，肝炎 B 疫苗作为一条治疗学的途径(疫苗的治疗) 予长期的 HBV 搬运人被以。疫苗的治疗的现在的政体是安全、便宜，然而并非那么有效。一支树枝状的基于房间的治疗学的疫苗最近为治疗长期的 HBV 感染被开发了。在这评论，我们将为治疗长期的 HBV 感染包括疫苗的治疗和树枝状的基于房间的疫苗的治疗关于 HBV 特定的有免疫力的治疗的开发的概念，科学逻辑，策略和技术讨论。